ORTEXORTEX News
Tracking LITE? Get live short interest, options flow, and signals on ORTEX.Sign up free →
LI
Trader NoteLITE

Lumentum drops 17% in a week as analysts lift targets and shorts hold steady

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 21 Oct 2026, 20:03

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

LITE fell 16.7% over the past week to $822.51, a sharper move than any of its closest peers and one that sits awkwardly against a backdrop of rising analyst price targets and short interest that barely budged.

The contrast with the Street is stark. Jefferies raised its target to $1,250 on Wednesday, Stifel lifted to $1,232 earlier this month, and Citigroup moved its target all the way to $1,400 in late September. The consensus mean target is $1,165, implying roughly 42% upside from Tuesday's close. Five analysts rate the stock a Hold, and the bull case centres on gross margins crossing 45% next quarter, driven by 200G EML pricing and better factory utilisation, with guided sequential revenue growth of around $140 million. The bear case is familiar: EML chip supply constraints in the Datacom segment, concentration risk with a handful of large cloud customers, and the possibility that capex budgets at those customers get trimmed. Morgan Stanley and TD Cowen have the most cautious targets in the recent sample, at $1,000 and $820 respectively, both stale enough to note that their last updates came in August. The PE multiple has compressed nearly three points over the past month to 24.7x, and EV/EBITDA has dropped 1.6 points to 16.5x, consistent with a stock that has been re-rated down even as the earnings-revision picture over 90 days remains strong, ranking in the 90th percentile on that factor.

Short positioning has not meaningfully responded to the price drop. Short interest is 10.3% of free float, up roughly 4% over the past month but essentially flat over the past week. The borrow market is loose. Availability runs at over 1,100%, meaning there are more than eleven shares available to borrow for every one already lent out, well above the 52-week trough of 140%. Cost to borrow is 0.54%, low by any standard, despite rising 24% over the past month in absolute terms. The options market adds little urgency: the put/call ratio of 1.07 is essentially in line with its 20-day average, and the z-score of 0.02 is negligible. This is not a market leaning hard against the stock. The ORTEX short score is 44, in the middle of the historical range, and has barely moved this week.

Retail attention is an outlier. The ORTEX alt-data layer flags a Wikipedia-views z-score of 2.6 against the stock's own 90-day history, a two-and-a-half-standard-deviation spike in retail interest as of October 19. This is an attention signal, not a revenue indicator, but it is the kind of reading that tends to accompany sharp price moves, and it is the sharpest reading in the current snapshot.

The peer selloff gives some context to the magnitude of this week's drop, but not all of it. AAOI fell 21.5% over the same period, SILC dropped 26%, VIAV lost 15.9%, and CIEN shed 14.6%. The median move across the group is around 13% to 15% negative. LITE's 16.7% decline is on the worse end but not an extreme outlier relative to the group, suggesting the sector rather than company-specific news drove most of the move. Where LITE does separate from peers is in the scale of the analyst re-rating it received this year: a 151% year-to-date gain through mid-September meant the stock entered this week's selloff carrying a far richer valuation than names like Viavi or Ciena.

Insider activity over the past 90 days is net negative to the tune of roughly $79 million in sales, but every transaction in the record is flagged as executed under a pre-arranged 10b5-1 plan. The CFO sold 24,542 shares at $1,048.50 on October 1, and President of Global Business Units Wupen Yuen has run a steady programme of 500-share daily sales since September. Planned sales of this kind carry limited informational content about near-term conviction.

The next earnings date is November 5. With the stock now trading 29% below the consensus target, the key question heading into that print is whether gross margins deliver the above-45% reading the bull case requires, or whether the supply chain caveats the bears cite show up in the Components segment numbers.

Stocks in this article

See the live data behind this article on ORTEX.

Open LITE on ORTEX →

How this article was generated

Generated
21 Oct 2026, 20:11
Data as of
21 Oct 2026, 20:03
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.